236 TWELVE-WEEK COURSE OF PIFN-α-2A/RIBAVIRIN IS AN OPTIMIZED REGIMEN FOR TREATMENT OF HCV GENOTYPE 2 BUT NOT GENOTYPE 3 NON-CIRRHOTIC PATIENTS WITH RVR
L.E. Adinolfi, R. Zampino, B. Guerrera, L. Restivo, L. Rinaldi, A. Ciervo, V.R. Scialdone, M. Ferrara, G. RuggieroVolume:
52
Year:
2010
Language:
english
DOI:
10.1016/s0168-8278(10)60238-3
File:
PDF, 64 KB
english, 2010